LSKB TO REPORT PHASE 2 APATINIB CLINICAL DATA AT 2016 ESMO CONGRESS
SALT LAKE CITY, September 21, 2016 – LSK BioPharma (LSKB) announced that it will release data from its phase 2 apatinib clinical trial in a poster at the 2016 ESMO Congress in Copenhagen, Denmark October 7-11, 2016.
This data comes from patients that were enrolled in a phase 1/2a study of apatinib. Thirty subjects were enrolled in part 2 from August 2014 to December 2014. With several patients responding to apatinib and electing to continue therapy, the study completed in the first quarter of 2016. Patients with gastric cancer, NSCLC, neuroendocrine tumor, mesothelioma, and colorectal cancer were evaluated in this study.
“We are very encouraged with our clinical experience of apatinib,” said Scott Houston, head of clinical development at LSKB, “We feel this study in the US and Korea underscores the clinical activity and the tolerability of apatinib in solid tumors.”
About Apatinib
Apatinib is the first successful small-molecule angiogenesis inhibitor in gastric cancer. It has been approved in China (advanced gastric cancer, Dec 2014) by the Chinese-territory license-holder Jiangsu Hengrui. LSK BioPharma, which holds the global rights (ex-China), has completed phase 1/2a clinical studies under a U.S. FDA IND and is planning to initiate multiple late stage clinical trials in gastric cancer (global pivotal trial), colorectal cancer, and hepatocellular carcinoma. LSKB has partnered development and marketing in Korea with Bukwang Pharma. Apatinib acts by inhibiting angiogenesis in solid tumors. Angiogenesis is a critical process in cancer growth and proliferation, as tumors cannot grow beyond 1-2mm3 without sufficient blood supply. Apatinib acts by selectively inhibiting VEGFR-2 which is primarily responsible for tumor-mediated angiogenesis. Apatinib has been tested in almost 1,000 patients worldwide and has demonstrated efficacy in numerous cancers including gastric cancer, colorectal cancer, HCC, NSCLC, breast cancer, mesothelioma, and neuroendocrine tumors.
About LSK BioPharma
LSKB is a privately-held biopharmaceutical company based in Salt Lake City, Utah. The Company specializes in the early clinical development of promising therapies for unmet medical needs in cancer. LSKB is developing two exciting drug candidates; a small molecule angiogenesis inhibitor with potential to treat a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. LSKB can be found on the web at www.lskbiopharma.com.
Contact:
Angie Price
angieprice@lskbiopharma.com
